医学
奥拉帕尼
贝伐单抗
卵巢癌
肿瘤科
内科学
维持疗法
佐剂
耐火材料(行星科学)
癌症
化疗
聚ADP核糖聚合酶
基因
物理
化学
天体生物学
聚合酶
生物化学
出处
期刊:PubMed
日期:2019-05-01
卷期号:17 (5.5): 619-621
被引量:43
标识
DOI:10.6004/jnccn.2019.5018
摘要
After 3 to 4 decades of stagnation, several new options are available for the treatment of ovarian cancer, some of which produce longer survival compared with historical controls. Additionally, 3 new PARP inhibitors (olaparib, rucaparib, niraparib) have been approved for use in ovarian cancer, with different indications as maintenance therapy or treatment of recurrence. Indications for bevacizumab have been extended, and there are now multiple combination chemotherapy regimens that include bevacizumab as part of initial treatment and as an option for maintenance therapy in select patients, both for first-line primary/adjuvant chemotherapy and for treatment of recurrent or refractory disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI